For patients with nonvalvular atrial fibrillation (NVAF),
ONLY ELIQUIS
DELIVERS BOTH
The ONLY anticoagulant that demonstrated
superiority in BOTH stroke/systemic
embolism and major bleeding vs warfarin.1
SUPERIOR
Risk reduction in
stroke/systemic
embolism
vs warfarin1
1.27%/year vs 1.60%/year; P=0.01
HR†=0.79 (95% CI,‡ 0.66, 0.95);
21% RRR§; 0.33%/year ARR||
PRIMARY EFFICACY OUTCOME
Superiority to
warfarin was
primarily
attributable to
a reduction in
hemorrhagic stroke
and ischemic strokes
with hemorrhagic
conversion compared
to warfarin. Purely
ischemic strokes
occurred with similar
rates on both drugs.1
SUPERIOR
Based on
fewer major
bleeding* events
vs warfarin1
2.13%/year vs 3.09%/year; P<0.0001
HR=0.69 (95% CI, 0.60, 0.80);
31% RRR; 0.96%/year ARR
PRIMARY SAFETY OUTCOME
In another clinical
trial, AVERROES®,
ELIQUIS was
associated
with an increase
in major bleeding
compared to
aspirin that was not
statistically significant
(1.41%/year vs O.92%/
year, HR=1.54 [95% CI,
0.96, 2.45]; P=0.07).1
The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE, this occurred in 1.7%
and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively.
*Major bleeding was defined as clinically overt bleeding accompanied by one or more of the
following: bleeding that was fatal; bleeding that occurred in at least one critical site (critical
sites included intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular
with compartment syndrome, retroperitoneal); a transfusion of 2 or more units of packed red
blood cells; or a decrease in hemoglobin of 2 g/dL or more.
†
HR=hazard ratio; ‡CI=confidence interval; §RRR=relative risk reduction; ||ARR=absolute risk reduction.
hcp.eliquis.com
Connect with us to learn more about
ELIQUIS and our NVAF clinical trial program.